Medicine & Life Sciences
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
15%
Activated Protein C Resistance
27%
Antibodies
20%
Anticoagulants
100%
Antithrombins
14%
apixaban
32%
Atrial Fibrillation
15%
betrixaban
15%
Blood Platelets
10%
Contraceptives, Oral, Combined
18%
Coronavirus
19%
Dabigatran
75%
Dasatinib
14%
drospirenone
14%
ecarin
10%
edoxaban
22%
Estetrol
19%
Factor Xa Inhibitors
28%
Fibrinogen
10%
Hemorrhage
24%
Hemostasis
38%
Heparin
36%
Imatinib Mesylate
9%
Immunoglobulin G
17%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18%
Low Molecular Weight Heparin
18%
Meta-Analysis
13%
Neutralizing Antibodies
16%
Partial Thromboplastin Time
18%
ponatinib
17%
Prospective Studies
10%
Protein C
10%
Protein-Tyrosine Kinases
23%
Prothrombin Time
29%
Rivaroxaban
55%
SARS Virus
68%
Severe Acute Respiratory Syndrome
12%
Systematic Reviews
12%
Therapeutics
9%
Thrombin
61%
Thrombin Time
12%
Thrombocytopenia
12%
Thrombophilia
10%
Thrombosis
14%
Vaccination
14%
Vaccines
14%
Venous Thromboembolism
16%
Vitamin K
13%
Warfarin
11%
Chemical Compounds
Activated Partial Thromboplastin Time
10%
Antagonist
10%
Anticoagulant
10%
Anticoagulant Agent
40%
Antithrombin
5%
Coagulation
13%
Contraceptive Agent
5%
D Dimer
5%
Dabigatran
15%
Dabigatran Etexilate
14%
Dose
7%
Drug
7%
Fondaparinux
5%
Heparin
14%
Immunoassay
6%
Low Molecular Weight Heparin
15%
Plasma
10%
Plasma Concentration
7%
Protein C
11%
Prothrombin
8%
Rivaroxaban
26%
Thrombin
10%
Thrombotic
8%
Time
6%
Warfarin
7%